High rate of non-treatment among osteoporotic women enrolled in a US Medicare plan

References

• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014;29:2520-6
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004
   Google Scholar
• Endo Y, Aharonoff GB, Zuckerman JD, et al. Gender differences in patients with hip fracture: a greater risk of morbidity and mortality in men. J Orthop Trauma 2005;19:29-35
   PubMed Web of Science ®Google Scholar
• Schousboe JT. Epidemiology of vertebral fractures. J Clin Densitom 2016;19:8-22
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359-81
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465-75
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010;16(Suppl 3):1-37
   PubMedGoogle Scholar
• Gleason LJ, Menzies IB, Mendelson DA, et al. Diagnosis and treatment of osteoporosis in high-risk patients prior to hip fracture. Geriatr Orthop Surg Rehabil 2012;3:79-83
   PubMedGoogle Scholar
• Greenspan SL, Wyman A, Hooven FH, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc 2012;60:455-61
   PubMed Web of Science ®Google Scholar
• Guggina P, Flahive J, Hooven FH, et al. Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone 2012;51:975-80
   PubMed Web of Science ®Google Scholar
• Petrella RJ, Jones TJ. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam Pract 2006;7:31
   PubMedGoogle Scholar
• Simonelli C, Chen YT, Morancey J, et al. Evaluation and management of osteoporosis following hospitalization for low-impact fracture. J Gen Intern Med 2003;18:17-22
   PubMed Web of Science ®Google Scholar
• Singh S, Foster R, Khan KM. Accident or osteoporosis?: Survey of community follow-up after low-trauma fracture. Can Fam Physician 2011;57:e128-33
   PubMed Web of Science ®Google Scholar
• Teede HJ, Jayasuriya IA, Gilfillan CP. Fracture prevention strategies in patients presenting to Australian hospitals with minimal-trauma fractures: a major treatment gap. Intern Med J 2007;37:674-9
   PubMed Web of Science ®Google Scholar
• Kroth PJ, Murray MD, McDonald CJ. Undertreatment of osteoporosis in women, based on detection of vertebral compression fractures on chest radiography. Am J Geriatr Pharmacother 2004;2:112-18
   PubMedGoogle Scholar
• Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-7
   PubMed Web of Science ®Google Scholar
• Premaor MO, Pilbrow L, Tonkin C, et al. Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service. QJM 2010;103:33-40
   PubMed Web of Science ®Google Scholar
• Luthje P, Nurmi-Luthje I, Kaukonen JP, et al. Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr 2009;49:153-7
   PubMed Web of Science ®Google Scholar
• Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004;15:120-4
   PubMed Web of Science ®Google Scholar
• Siris ES, Modi A, Tang J, et al. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Curr Med Res Opin 2014;30:123-30
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Types of osteoporosis medications. Washington, DC, USA: National Osteoporosis Foundation, 2014. Available at: http://nof.org/articles/22 [Last accessed 26 July 2015]
   Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-62
   PubMed Web of Science ®Google Scholar
• Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245-56
   PubMed Web of Science ®Google Scholar
• Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377-82
   PubMed Web of Science ®Google Scholar
• Siris ES, Yu J, Bognar K, et al. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage. Clin Interv Aging 2015;10:1813-24
   PubMed Web of Science ®Google Scholar
• Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334-8
   PubMed Web of Science ®Google Scholar
• Block AE, Solomon DH, Cadarette SM, et al. Patient and physician predictors of post-fracture osteoporosis management. J Gen Intern Med 2008;23:1447-51
   PubMed Web of Science ®Google Scholar
• Asche C, Nelson R, McAdam-Marx C, et al. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 2010;21:1427-36
   PubMed Web of Science ®Google Scholar
• Martin KE, Yu J, Campbell HE, et al. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm 2011;17:596-609
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Curtis JR, Yu J, et al. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy. Appl Health Econ Health Policy 2012;10:163-73
   PubMedGoogle Scholar
• Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 2012;50:870-5
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
   PubMed Web of Science ®Google Scholar
• Meadows ES, Mitchell BD, Bolge SC, et al. Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. BMC Womens Health 2012;12:1
   PubMed Web of Science ®Google Scholar
• Modi A, Siris ES, Tang J, et al. Gastrointestinal events and association with initiation of treatment for osteoporosis. ClinicoEconomics Outcomes Res 2015;7:603-13
   PubMedGoogle Scholar
• Haasum Y, Fastbom J, Fratiglioni L, Johnell K. Undertreatment of osteoporosis in persons with dementia? A population-based study. Osteoporos Int 2012;23:1061-8
   PubMed Web of Science ®Google Scholar
• Yu J, Goldshtein I, Shalev V, et al. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women. Int J Clin Pract 2015;69:1007-14
   PubMed Web of Science ®Google Scholar
• Hall KE, Proctor DD, Fisher L, Rose S. American gastroenterological association future trends committee report: effects of aging of the population on gastroenterology practice, education, and research. Gastroenterology 2005;129:1305-38
   PubMed Web of Science ®Google Scholar
• Modi A, Siris S, Yang X, et al. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population. J Manag Care Specialty Pharm 2015;21:499-506
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8
   PubMed Web of Science ®Google Scholar
• Reynolds K, Muntner P, Cheetham TC, et al. Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 2013;24:2509-17
   PubMed Web of Science ®Google Scholar
• Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis – where do we go from here? N Engl J Med 2012;366:2048-51
   PubMed Web of Science ®Google Scholar